Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01934725
Other study ID # SECRETO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 2013
Est. completion date December 2031

Study information

Verified date November 2023
Source SECRETO Study Consortium
Contact Jukka Putaala, A/Prof.
Phone +35894711
Email jukka.putaala@hus.fi
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes occur at younger ages. Stroke at young age causes marked disability at worst and thus long-standing socioeconomic consequences and exposes survivors for 4-fold risk of premature death compared with background population. Up to 50% of young patients with ischemic stroke remain without definitive etiology for their disease despite extensive modern diagnostic work-up (i.e. cryptogenic stroke). The group of cryptogenic strokes includes those with patent foramen ovale (PFO) or other abnormalities in the atrial septum in the heart as the only or concomitant finding. Population prevalence of PFO is high, 25%, and the mechanisms how PFO would be associated causally with ischemic stroke remain to be clarified. Moreover, there are only scarce data on clinical outcome, long-term risk of new vascular events, and prevention of such events in these patients. DESIGN: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO) is an international prospective multicenter case-control study of young adults (age 18-49) presenting with an imaging-positive first-ever ischemic stroke of undetermined etiology (aim N=2000). Patients are included after standardized diagnostic procedures (brain MRI, imaging of intracranial and extracranial vessels, cardiac imaging, and screening for coagulopathies) and age- and sex-matched to healthy controls in a 1:1 fashion. Up to 45 study sites worldwide will be needed to recruit the planned participant population during a 3-year period. Neurovascular imaging and echocardiography studies, and ECGs will be read centrally. AIMS: SECRETO involves five principal fields of investigation: (1) Stroke triggers and clinical risk factors; (2) Long-term prognosis (new vascular events, functional and psychosocial outcomes); (3) Abnormalities of thrombosis and hemostasis; (4) Biomarkers of e.g. inflammation, atherogenesis, endothelial function, thrombosis, platelet activation, and hemodynamic stress to characterize postulated cryptogenic stroke mechanisms; and (5) genetic study, including genome-wide association and candidate gene studies as well as next-generation sequencing approach. All analyses consider cardiac functional and interatrial structural properties as a possible mediator. Furthermore, SECRETO Family Study (substudy) aims at collecting extensive family history of thrombotic events from informative patients being screened for SECRETO main study and collect genetic samples from all consenting family members for whole-genome sequencing. SIGNIFICANCE: SECRETO will provide novel information on clinical and subclinical risk factors, both transient and chronic, predisposing to cryptogenic ischemic stroke in young adults. This study also reveals long-term prognosis of this understudied patient population and may discover new genetic background underlying the disease mechanism and provide potential targets for drug development.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date December 2031
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility PATIENTS: Inclusion Criteria: 1. Age 18 to 49 at stroke onset 2. Patient hospitalized due to first-ever imaging-positive ischemic stroke of undetermined etiology after complete timely diagnostic testing. Exclusion Criteria: 1. Baseline mandatory tests not obtained in the first week following stroke onset, including: - Brain MRI - Routine blood tests, including complete blood count, CRP, fasting glucose, creatinine, aPTT, INR, total cholesterol, LDL-cholesterol, HDL-cholesterol, HbA1C, hemoglobin electrophoresis in individuals of African origin 2. Other baseline mandatory tests not obtained within the first two weeks following stroke onset, including: - Imaging of cervicocephalic arteries by CTA, MRA, or DSA - Transesophageal (highly recommended) or transthoracic echocardiography - 24-hour Holter monitoring or continuous in-hospital ECG monitoring with automated arrhythmia detection for at least 24 hours - Screening for thrombophilia, including antiphospholipid antibodies and other coagulopathies (any abnormal finding must be retested at mandatory 3-month follow-up visit >12 weeks from initial testing or >4 weeks after cessation of anticoagulation at any later time point); mandatory tests include anticardiolipin antibodies, lupus anticoagulant, anti-ß2-glycoprotein antibodies, factor V mutation (or aPC resistency ruled out), factor II mutation, homocysteine, antithrombin III, protein C, and protein S 3. No evidence of current brain ischemia 4. Current stroke due to cerebral venous thrombosis or as a complication of subarachnoid hemorrhage, angiography, or cardiac surgery 5. Patient otherwise not eligible for the study or adherent for follow-up (eg nonresident) or has concurrent disease affecting outcome (eg multiple sclerosis, cancer) 6. Informed consent not obtained from the patient or a proxy. CONTROL SUBJECTS: Inclusion Criteria: 1. Age 18 to 49 years 2. Absence of prior ischemic stroke as ascertained using the Questionnaire for Verifying Stroke-Free Status Exclusion Criterion: 1. Informed consent not obtained

Study Design


Locations

Country Name City State
Estonia Tartu University Hospital Tartu
Finland Helsinki University Central Hospital Helsinki
Finland Kuopio University Hospital Kuopio
Finland Oulu University Hospital Oulu
Finland Tampere University Hospital Tampere
Finland Turku University Central Hospital Turku
Germany Ernst-Moritz-Arndt University Medicine Greifswald
Greece "Attikon" Hospital, University of Athens, School of Medicine Athens
Italy University of Brescia Brescia
Italy Arcispedale S. Maria Nuova Reggio Emilia
Lithuania Vilnius University Hospital Santariskiu klinikos Vilnius
Netherlands Radboud University Nijmegen Medical Centre Nijmegen
Norway Haukeland University Hospital Bergen
Portugal Hospital Santa Maria Lisboa
Spain Torrecárdenas University Hospital Almería
Sweden Sahlgrenska University Hospital Gothenburg
Turkey Istanbul University Istanbul Faculty of Medecine Istanbul
United Kingdom Peterborough City Hospital Peterborough
United Kingdom Royal Stoke University Hospital Stoke-on-Trent

Sponsors (9)

Lead Sponsor Collaborator
SECRETO Study Consortium Academy of Finland, Finnish Medical Foundation, Hospital District of Helsinki and Uusimaa, Hospital District of North Ostrobothnia, Hospital District of Southwestern Finland, Northern Savo Hospital District, Pirkanmaa Hospital District, Sahlgrenska University Hospital, Sweden

Countries where clinical trial is conducted

Estonia,  Finland,  Germany,  Greece,  Italy,  Lithuania,  Netherlands,  Norway,  Portugal,  Spain,  Sweden,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Modified Rankin Scale Functional outcome will be assessed with modified Rankin Scale at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10. 10 years
Other Vocational outcome Vocational status will be assessed at each follow-up contact with Poststroke Working Activity Questionnaire and a set of questions designed for the study. 10 years
Other Cognitive outcome Cognition will be assessed at mandatory 3-month follow-up visit (Montreal Cognitive Assessment). 3 months
Other Anxiety and depression Poststroke anxiety and depression will be evaluated at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with Hospital Anxiety and Depression Scale. 10 years
Other Quality of life Quality of life will be assessed at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with EuroQol questionnaire. 10 years
Other Caregiver burden Poststroke burden to caregiver will be assessed at 3-month visit with Expanded Caregiver Strain Index Questionnaire. 3 months
Other Barthel Index Functional outcome will be assessed with Barthel Index at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10. 10 years
Primary Nonfatal or fatal recurrent ischemic cerebrovascular event Ischemic stroke or transient ischemic attack 10 years
Secondary Composite of noncerebrovascular arterial or venous thrombotic events, or cerebral venous thrombosis 10 years
Secondary Death from any cause 10 years
Secondary New-onset atrial fibrillation 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A

External Links